
THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. Use of an aqueous preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof,



Formula (I)

wherein R_1 is H or C_{1-4} alkyl, in the manufacture of a medicament for reducing intracranial pressure (ICP) in a subject which presents with an ICP level of above 20 mm Hg, wherein the medicament is to be parenterally administered to said subject for up to 30 minutes; wherein the parenteral administration is intravenous administration; and wherein the medicament is administrable at a dose of 30 mg to 200 mg of a compound of formula (I), or a pharmaceutically acceptable salt thereof, via infusion or 1 mg to 40 mg of a compound of formula (I), or a pharmaceutically acceptable salt thereof, via injection.

2. A use according to claim 1, wherein administration is for up to about 15 minutes.

3. A use according to claim 1 or 2, wherein the medicament is administrable at a dose of 30 mg to 200 mg of a compound of formula (I), or a pharmaceutically acceptable salt thereof, via infusion.

4. A use according to any one of claims 1 to 3, wherein the medicament is administrable at a dose of 90 mg to 150 mg of a compound of formula (I), or a pharmaceutically acceptable salt thereof, via infusion.


5. A use according to any one of claims 1 to 4, wherein the administration of the medicament is to be repeated at least 1 more time about 4 hours from the first administration.


6. A use according to any one of claims 1 to 5, wherein the administration of the medicament is to be repeated at least 1 more time about 4 hours from the first administration for two to four consecutive days.


7. A use according to claim 1 or claim 2, wherein the medicament is administrable at a dose of 1 mg to 40 mg of a compound of formula (I), or a pharmaceutically acceptable salt thereof, via injection.


8. A use according to claim 7, wherein the administration of the medicament is to be repeated at least 1 more time about 4 hours from the first injection.

9. A use according to any one of claims 1 to 8, wherein the compound of Formula (I) is selected from:










.

10. A use according to claim 9, wherein the compound of Formula (I) is



11. A use according to any one of claims 1 to 10, wherein the administration of the medicament achieves a reduction of ICP of below 20 mmHg.

12. A use according to any one of claims 1 to 11, wherein the administration of the medicament achieves a reduction of ICP of below 20 mmHg for 5-10hrs.

13. A use according to any one of claims 1 to 12, wherein the subject receives the administration within 1-48 hrs after being involved in a TBI or having a stroke.

14. A use according to any one of claims 1 to 13, wherein the medicament is for treating concussion, post-concussive (or post-concussion) syndrome (PCS), chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI) and/or stroke.